Live Breaking News & Updates on Sanofi genzyme medical

Stay informed with the latest breaking news from Sanofi genzyme medical on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Sanofi genzyme medical and stay connected to the pulse of your community

Sanofi Q1 Profit Weak, But Sales Rise; Backs FY24 View; Stock Up

French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq.

France , Paris , France-general- , French , Paul-hudson , Nasdaq , Chief-executive-officer , Consumer-healthcare , Mental-wellness , Digestive-wellness , Sanofi , Rug-major

Sanofi reports 1Q revenue increase, as sales of vaccines, Dupixent rise

Sanofi has moved past the pandemic and expects no COVID-19 revenue in 2024.

Paris , France-general- , France , New-york , United-states , Monroe-county , Paul-hudson , Sanofi-pasteur , Regeneron-pharmaceuticals-of-tarrytown , Regeneron-pharmaceuticals , Sanofi , Ocono-township

RSV vaccine boosts Monroe County's Sanofi Pasteur

Sanofi has moved past the pandemic and expects no COVID-19 revenue in 2024.

Paris , France-general- , France , United-states , New-york , Monroe-county , American , Paul-hudson , Sanofi-pasteur , Drug-administration , Regeneron-pharmaceuticals-of-tarrytown , Chief-executive-paul-hudson

Sanofi: Rilzabrutinib LUNA 3 Phase 3 Study Meets Primary Endpoint In Immune Thrombocytopenia

Sanofi - Aventis Groupe said results from the LUNA 3 phase 3 study showed that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia.

More-such-health-news , Fast-track-designation , Orphan-drug , Sanofi , Ilzabrutinib ,

Sanofi India: Sanofi looks for accelerated growth in India; plans fast-tracking of product pipeline

Sanofi, a leading French pharmaceutical company, aims to expand its presence in the Indian market by introducing new drugs, enhancing localization efforts, and collaborating with domestic firms. Managing Director Rodolfo Hrosz highlights the significant growth potential in India and emphasizes the company's focus on addressing the diabetes segment.

France , India , French , Rodolfo-hrosz , Cipla , Sanofi-india-managing-director-rodolfo-hrosz , Healthcare-india , Sanofi-india , Sanofi , Hrosz , Sanofi-healthcare-india , Soliqua

Sanofi says to reach settlement on Zantac lawsuits in US

French pharmaceutical giant Sanofi said Thursday it had reached a preliminary agreement on settling thousands of US lawsuits concerning its heartburn drug Zantac.

Canada , United-kingdom , Vietnam , Republic-of , Delaware , United-states , Long-chau , Han-i , Paris , France-general- , France , British

Sanofi gets nod for new polio vaccine in India

To ensure that there is no interruption to the availability of IPV vaccines, the French firm has already obtained approvals for IMOVAX-Polio.

France , India , Hyderabad , Andhra-pradesh , French , Sanofi-healthcare-india-pvt-ltd , Serum-institute-of-india , Inactivated-polio-vaccine , Sanofi-india , Serum-institute , Sanofi

Sanofi gets nod for injectable Polio vaccine

The announcement comes a day after ET reported that the company had ceased production of its ShanIPV vaccines in India, which may lead to a potential shortage in the country.

India , France , French , Sanofi , Vaccine , Polio-vaccine , Polio , Vaccine-doses ,

polio vaccine: Polio vaccine shortage looms over India with Sanofi plants' shutdown

An impending crisis looms over India's supply of injectable poliomyelitis vaccine (IPV) as French drugmaker Sanofi has shut down its manufacturing plants in the country, halting production of its IPV brand ShanIPV in December 2023. Sanofi's closure has raised concerns about disruptions in India's polio eradication efforts, as it catered to over 80% of the country's IPV dose requirements.

Pune , Maharashtra , India , Medchal , Andhra-pradesh , France , Telangana , French , Sanofi-pasteur , Serum-institute-of-india , India-universal-immunization-programme , Serum-institute

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK (Reuters) -Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday. Sanofi did not disclose the financial terms of the deal. The agreement, which still needs to be finalized, will resolve most of the lawsuits against the French pharmaceutical company in U.S. state courts, with the exception of Delaware where the majority of the cases are pending.

Delaware , United-states , Chris-reese , Dietrich-knauthediting , Reuters , Sanofi , Oehringer-ingelheim , Ennifer-moore , Ancer , Antac , Elaware-superior-court , Laintiffs